Exor Raises Stake in bioMérieux to 8.53%
The Agnelli family investment arm is increasing its holding through an exchange of its Institut Mérieux shares and voting rights for bioMérieux shares.
Updated on Nov. 19, 2026 in Corporate Finance

Exor is raising its stake in bioMérieux to 8.53% from 3.87% through an exchange of its shares and voting rights in Institut Mérieux for shares in bioMérieux. The transaction is expected to be completed in December.
Why it matters
The move positions Exor as a long-term investor in bioMérieux, a company whose largest holder remains Institut Mérieux with 55.24% of capital and 68.67% of voting rights. It reflects a consolidation of the investment arm's exposure to the diagnostics company.
The disclosure reports Exor's bioMérieux stake rising to 8.53% from 3.87%, with expected voting rights of 5.35% after completion. The transaction has not closed, and completion is expected in December.
The players
Exor
Exor is the investment holding company of the Agnelli family in Italy, with a portfolio spanning several sectors.
Institut Mérieux
Institut Mérieux is a French foundation-linked holding entity that controls the majority of bioMérieux's capital and voting rights.
bioMérieux
bioMérieux is a French company that develops in vitro diagnostic products for clinical and industrial testing.
The details
Exor is carrying out the increase by exchanging its shares and voting rights in Institut Mérieux for shares in bioMérieux. After the deal, Exor will hold 5.02% of Institut Mérieux's shares and 2.58% of its voting rights.
Timeline
November 19, 2026: Exor announced the stake increase in bioMérieux.
December 2026: Expected completion of the share exchange.
Market Dynamics
The transaction follows a pattern in which family holding companies restructure intermediate vehicles to raise direct exposure to listed operating companies. It indicates that Exor is seeking greater long-term influence in bioMérieux rather than exiting or trading the position.
Shareholders of bioMérieux and Institut Mérieux may see changes in the ownership balance once the exchange completes in December. Investors tracking the diagnostics sector should note the shift in controlling-stake dynamics between the two entities.
The takeaway
Large holding companies are increasingly using share exchanges to adjust their exposure to listed firms, so investors should watch for similar restructurings that can shift control dynamics without a new cash outlay.
What happens next
The share exchange transaction is expected to complete in December 2026, at which point Exor's bioMérieux voting rights are projected to rise to 5.35%.
Further reading
Explore more stories in Corporate Finance for context on similar shareholding moves.
Source note: This article includes information reported by Global Banking & Finance Review.



